

EBV viral capsid antigen (2E3): sc-80774

BACKGROUND

Epstein-Barr virus (EBV), also designated human herpesvirus 4 (HHV-4), is a member of the herpesvirus family and is one of the most common human viruses, infecting about 90% of the population. EBV infects only B lymphocytes and, though often asymptomatic, it can cause infectious mononucleosis, a disease characterized by fatigue, fever, sore throat and muscle soreness. The linear genome of EBV circularizes once it enters the cell and exists there as an episome. EBV may play a role in the development of both Burkitt lymphoma, a disease in which a tumor can form on the mandible or maxilla, and nasopharyngeal carcinoma, a tumor found in the upper respiratory tract, most commonly in the nasopharynx. The viral capsid antigen (VCA) of EBV is used as a marker for screening for viral infection as well as nasopharyngeal carcinoma, and many antigens from the viral capsid are used in diagnostic tests.

REFERENCES

- Luka, J., et al. 1986. Characterization of the restricted component of Epstein-Barr virus early antigens as a cytoplasmic filamentous protein. *J. Virol.* 58: 748-756.
- Goldschmidts, W.L., et al. 1989. Neutralization of Epstein-Barr virus-induced ribonucleotide reductase with antibody to the major restricted early antigen polypeptide. *Virology* 170: 330-223.
- Fan, J.A. 1990. Expression of the Epstein-Barr virus p150 viral capsid antigen in *Escherichia coli* for the use as antigen in diagnostic tests. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao* 11: 381-387.
- Gorgievski-Hrisoho, M., et al. 1990. Serodiagnosis of infectious mono-nucleosis by using recombinant Epstein-Barr virus antigens and enzyme-linked immunosorbent assay technology. *J. Clin. Microbiol.* 28: 2305-2311.
- Ruf, I.K., et al. 1999. Epstein-Barr virus regulates c-Myc, apoptosis, and tumorigenicity in Burkitt lymphoma. *Mol. Cell. Biol.* 19: 1651-1660.
- Tranchand-Bunel, D., et al. 1999. Detection of human antibodies using "convergent" combinatorial peptide libraries or "mixotopes" designed from a nonvariable antigen: application to the EBV viral capsid antigen p18. *J. Pept. Res.* 52: 495-508.
- Gan, Y.Y., et al. 2001. Epstein-Barr viral antigens used in the diagnosis of nasopharyngeal carcinoma. *J. Biomed. Sci.* 3: 159-169.
- Kantakamalakul, W., et al. 2001. Specific IgA antibody to Epstein-Barr viral capsid antigen: a better marker for screening nasopharyngeal carcinoma than EBV-DNA detection by polymerase chain reaction. *Asian Pac. J. Allergy Immunol.* 18: 221-226.
- Spender, L.C., et al. 2006. Cell target genes of Epstein-Barr virus transcription factor EBNA-2: induction of the p53 α regulatory subunit of PI 3-kinase and its role in survival of EREB2.5 cells. *J. Gen. Virol.* 87: 2859-2867.

SOURCE

EBV viral capsid antigen (2E3) is a mouse monoclonal antibody raised against EBV capsid antigen.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PRODUCT

Each vial contains 100 μ g IgG_{2a} in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

EBV viral capsid antigen (2E3) is recommended for detection of EBV viral capsid antigen of EBV origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) and immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

Molecular Weight of nonglycosylated VCA major capsid antigen: 150 kDa.

Molecular Weight of VCA glycoprotein: 110 kDa.

SELECT PRODUCT CITATIONS

- Feng, X., et al. 2011. Proteome profiling of Epstein-Barr virus infected nasopharyngeal carcinoma cell line: identification of potential biomarkers by comparative iTRAQ-coupled 2D LC/MS-MS analysis. *J. Proteomics* 74: 567-576.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.